Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a report issued on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock. Separately, Barclays reduced their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November […]

Leave a Reply

Your email address will not be published.

Previous post The Manitowoc Company, Inc. (NYSE:MTW) Receives Average Recommendation of “Reduce” from Brokerages
Next post Asbury Automotive Group, Inc. (NYSE:ABG) Given Consensus Rating of “Hold” by Analysts